Redeye provides its initial take on MedCap’s Q4 2025 report, which came in broadly in line with our estimates, with a slight beat in revenues and adjusted EBITA. Medtech outperformed while Speciality Pharma lagged our estimates, although all sectors grew Q/Q and Y/Y. Similarly, Medtech increased its adjusted EBITA margin while Specialty Pharma's decreased it compared with Q3 2025.
LÄS MER
